NewsBenzingaInvivyd And SPEAR Study Group Initiate FLINTLOCK Phase 2 Trial Evaluating Safety, Tolerability, Pharmacokinetics, And Clinical Efficacy Of High-Dose Monoclonal Antibody VYD2311 In Individuals With Long COVID Or Post-Vaccination Syndrome Invivyd And SPEAR Study Group Initiate FLINTLOCK Phase 2 Trial Evaluating Safety, Tolerability, Pharmacokinetics, And Clinical Efficacy Of High-Dose Monoclonal Antibody VYD2311 In Individuals With Long COVID Or Post-Vaccination Syndrome Benzinga 2026.10.14 11:05 (GMT+0) Open on Benzinga Other news Sell Eagle Point Credit Now – Match The Loss With Portfolio Gains To Lower Income Taxes 3 Bear Put Spread Trade Ideas For This Monday What to Expect From Coherent's Next Quarterly Earnings Report Netflix Stock Might be a Sleeper Hit 'Europe’s Top Carriers Explore Satellite Group to Fend Off SpaceX' - Bloomberg HC Wainwright & Co. Reiterates Buy on Zentalis Pharmaceuticals, Maintains $10 Price Target
